The incidence of multiple sclerosis (MS) is higher in women than in men (with a ratio of 2 : 1). However, although women show a benign course, men have a later onset and worse prognosis (1) . Indeed, physiological situations characterised by changes in sex steroid plasma levels (e.g. menstrual cycle, menopause, pregnancy, etc.) affect the disease course of MS (2-6) and, conversely, MS itself has an impact on sex steroid plasma levels (7) (8) (9) .
On this basis, protective effects of sex steroid hormones have been analysed and reported to be effective in experimental models of MS, such as experimental autoimmune encephalomyelitis (EAE) (10) (11) (12) (13) (14) (15) (16) . For example, progesterone (PROG) shows beneficial effects in EAE, inducing a better clinical score, reducing inflammatory cell infiltration and demyelinated plaques in the spinal cord, and increasing levels of Na + ,K + -ATPase mRNA a3 subunit (13) . PROG treatment also prevents axonal damage, increasing the number of small diameter axons and reducing the appearance of amyloid precursor protein and of GAP43 (12) . Furthermore, PROG exerts immunomodulatory effects, decreasing the secretion of pro-inflammatory cytokines [i.e. interleukin (IL)-2 and IL-17] and the expression of chemokine receptors (i.e. macrophage inflammatory protein-2, CC chemokine receptors 2 and 7) and increasing the levels of anti-inflammatory cytokines, such as IL- 10 (17) . Taken together, these results suggest that PROG may potentially represent a therapeutic tool for MS. However, it is important to highlight that these observations have been obtained in the acute phase of the disease, although it is well known that MS expresses different features depending on the phase (onset and relapse) of the disease. Most rat EAE models have been developed in Lewis and Dark Agouti (DA) strains. By contrast to what is observed in Lewis strain, DA rats show a protracted relapsing EAE, thus providing a model much closer to MS. As previously described (18) (19) (20) , between 14 and 20 days after myelin immunisation, multiple confluent foci of inflammation appear in many brain areas and spinal cord areas of DA rats as the result of a combined cellular attack on the central nervous system (CNS) by T cells, macrophages and auto-antibody producing plasma cells. In particular, a massive infiltration of inflammatory cells is observed around small blood vessels and in submeningeal areas, as well as in the grey matter of the spinal cord, whereas only small perivascular infiltrates were found in the white matter of the cerebellar peduncles (19) . Cell infiltration and high levels of cytokines persist after the clinical peak in the spinal cord (21) . Massive demyelinating lesions are also observed in the spinal cord at 14 and 21 days after myelin immunisation (22, 23) . Remyelination process starts relatively early in DA rats, although it is not yet completed at 40 days after myelin immunisation, as defined by molecular and morphological data (23) (24) (25) .
In the present study, we have analysed the effect of PROG treatment on the chronic phase of EAE (45 days after myelin immunisation) in DA rats. Clinical assessment and analyses in the spinal cord of the infiltration of inflammatory cells, microglial cell reactivity and cytokine expression, as well as the activity and expression of the Na + ,K + -ATPase pump and expression of myelin basic protein (MBP), were performed. Moreover, because in the nervous system the metabolism of PROG has a deep impact in its mechanism of action (26) , the levels of neuroactive steroid metabolites produced in the spinal cord were analysed by liquid chromatography tandem mass spectrometry (LC-MS ⁄ MS).
Materials and methods

Animal care and treatments
A total number of 24 male DA rats (180-200 g; Harlan, Correzzana, Italy), randomly assigned to one of the three groups described below, were used in the present study. Animals were housed in a limited access animal facility where room temperature and relative humidity were set at 22 AE 2°C and 55 AE 10%, respectively. Artificial lighting provided a 12 : 12 h light ⁄ dark cycle (lights on 07.00 h). The experimental plan was approved by the ad hoc committee of the University of Milano-Bicocca and the procedures were performed in accordance with EU Council directive 86 ⁄ 609 and with the Italian DL 116 ⁄ 1992. EAE was actively induced in 16 animals by s.c. inoculation into both hind limb footpads of syngenic spinal cord homogenate in incomplete Freund's adjuvant (IFA) (100 mg spinal cord homogenate ⁄ rat), whereas the remaining rats were not inoculated and were used as controls (n = 8).
Starting from the day of EAE induction, eight animals were administered every other day with 1 mg of PROG (Sigma, Milan, Italy) dissolved in 200 ll of sesame oil (i.e. they received a total of 21 s.c. injections). Eight EAE rats received vehicle only. Control rats (i.e. non-EAE animals) were also treated with vehicle. Rats were killed 24 h after the last treatment. All animals were sacrificed on day 45. We selected the 45-day time point because, after this period, it is very unusual to record new relapses in the DA model (27) .
Clinical assessment
The observation was protracted up to 45 days after EAE induction. The assessment of the clinical score was performed daily by the same examiner who was unaware of the group to which the animal under examination belonged. The score was assessed according to a scale in the range 0-5: 0 = healthy animals with no defective tail tonicity; 1 = limp tail; 2 = mild to moderate paraparesis of the hind limbs; 3 = paraplegia of the hind limbs; 4 = quadriplegia; 5 = moribund or dead (28) .
Pathological examination
According to a randomisation list designed before starting the experiment, animals were sacrificed on day 45, after they relapsed. The animals were anaesthetised by i.p. injection of ketamine ⁄ xylazine mixture. The spinal cord was then removed. Lumbar enlargement was fixed in 4% paraformaldehyde for 5 h and paraffin-embedded.
For histological examination, serial 5-lm thick sections were prepared and stained with haematoxylin and eosin (Bio-Optica, Milan, Italy) or with the Luxol fast blue (Bio-Optica) method to assess inflammation and demyelination, respectively.
Immunohistochemistry assay
An immunohistological characterisation of the infiltrating cells was performed using anti-CD3 (rabbit anti-rat polyclonal antibody; Abcam, Cambridge, UK) and anti-ED1 (mouse anti-rat monoclonal antibody; Abcam) antibodies for detecting T cells and microglia ⁄ macrophages. Paraffin sections were deparaffinised with xylene, rehydratated and boiled in a microwave oven (3 · 5 min in 1 mM ethylenediaminetetraacetic acid, pH 8) to retrieve antigens. Endogenous peroxidase activity was quenched by incubation in 3% H 2 O 2 for 5 min at room temperature (RT). The slides were washed in Trisbuffered saline (Tris-HCl pH7.5, NaCl 0.138 M, KCl 0.02 M) and incubated with 5% normal goat serum (NGS) in TBS for 1 h at RT. The sections were incubated with primary antibodies overnight at 4°C (anti-CD3, dilution 1 : 100; anti-ED1, dilution 1 : 300; diluted in 1% NGS in TBS). Then the slides were washed in 1% NGS and incubated with secondary biotinylated anti-mouse or anti-rabbit immunoglobulin (Ig)G (dilution 1 : 200; Abcam) for 1 h at RT, followed by an incubation with streptavidin-peroxidase for 45 min at RT. The antigen-antibody complex was visualised by incubating the sections with 3,3¢-diaminobenzidine hydrochloride (Sigma, St Louis, MO, USA) dissolved in 30 ml of TBS with 10 ll of 3% H 2 O 2 . Rat spleen sections were used as positive controls. Negative controls were incubated only with secondary biotinylated anti-mouse or anti-rabbit IgG. Sections were then counterstained within haematoxylin, mounted in DPX (Sigma) and examined on a Nikon E200 photomicroscope (Nikon, San Giovanni Valdarno, Italy).
For assessment of major histocompatability complex (MHC)-II immunoreactive cells, transversal sections of the spinal cord, 50 lm thick, were obtained using a Vibratome (VT 1000 S; Leica Microsystems, Wetzlar, Germany). Immunohistochemistry was carried out in free-floating sections under moderate shaking. The endogenous peroxidase activity was quenched for 10 min at RT in a solution of 3% hydrogen peroxide in 30% methanol. After several washes in 0.1 M phosphate buffer (pH 7.4), containing 0.3% bovine serum albumin, 0.3% triton X-100 and 0.9% NaCl (washing buffer), sections were incubated overnight at 4°C with a mouse monoclonal antibody for MHC-II (dilution 1 : 300, MRC-OX6, MCA46G; Serotec, Bicester, UK), diluted in washing buffer containing 3% NGS. After incubation with the primary antibody, sections were then rinsed in buffer and incubated for 2 h at RT with biotinylated goat anti-mouse immunoglobulin G (dilution 1 : 250 in washing buffer, 31800; Pierce, Rockford, IL, USA). After several washes in buffer, sections were incubated for 90 min at RT with avidin-biotin-peroxidase complex (dilution 1 : 250, ImmunoPure ABC peroxidase staining kit; Pierce). The reaction product was revealed by incubating the sections with 2 lg ⁄ ml 3,3¢-diaminobenzidine (Sigma-Aldrich Química, Tres Cantos, Madrid, Spain) and 0.01% hydrogen peroxide in 0.1 M phosphate buffer. Then sections were dehydrated and mounted on gelatinised slides.
Morphometric analysis
The number of MHC-II immunoreactive cells was assessed in the white matter region located between the dorsal horns. The number of MHC-II immunoreactive cells was estimated by the optical disector method (29) using total section thickness for disector height (30) and a counting frame of 50 · 50 lm. A total of nine counting frames were assessed per animal. Section thickness was measured using a digital length gauge device (Heidenhain-Metro MT 12 ⁄ ND221; Heidenhain, Traunreut, Germany) attached to the stage of a Leitz microscope. Cell nuclei from MHC-II immunoreactive cells that came into focus when focusing down through the disector height were counted. All counts were performed on coded sections.
Real-time polymerase chain reaction (PCR)
Total RNA from snap-frozen spinal cord was extracted using the standard Trizol protocol based on the method developed by Chomczynski and Sacchi (31) . RNA was subsequently extracted in accordance with the manufacturer's protocol (Invitrogen, San Giuliano Milanese, Italy). The precipitated RNA was dissolved in RNase-free water, quantified and aliquots were prepared for further analysis. A 5-lg aliquot of each sample was treated with DNase (AMPD1 DNase I; Amplification Grade; Sigma-Aldrich, St Louis, MO, USA) to avoid DNA contamination and quantified again. RNA was analysed using a TaqMan quantitative real-time PCR instrument (CFX384 real time system; Bio-Rad Laboratories, Segrate, Italy) using the iScriptTM one-step RT-PCR kit for probes (Bio-Rad Laboratories). Samples were run in 384 well formats in triplicate as multiplexed reactions with a normalising internal control (18s rRNA), with the exception of tumour necrosis factor (TNF)-a, which was run in triplicate but as simplex. IL-1b (Rn00580432_m1), TNF-a (Rn99999017_m1), transforming growth factor-b1 (Rn00572010_m1) specific TaqMan MGB probe were purchased from Applera (Monza, Italy).
Na + ,K + -ATPase activity
Spinal cords were homogenised in a chilled solution containing 0.25 M sucrose, 1.25 mM ethyleneguaninetetraacetic acid and 10 mM Tris, pH 7.5, at 1 : 20 (w ⁄ v) in a glass-glass Elvehjem-Potter homogeniser (DISA, Milan, Italy), and stored at )80°C for ATPase determination. Na + ,K + -ATPase activity was determined spectrophotometrically as described previously (32) . Protein content in homogenates was determined by Bradford method with bovine serum albumin as standard (33) .
Western blotting
The lumbar portion of spinal cord was homogenised on ice in excess of lysis buffer [phosphate-buffered saline (PBS), pH 7.4, added with 1% Nonidet P-40] supplemented with protease cocktail inhibitor (Roche Diagnostic spa, Monza, Italy), with an ultra turrax homogeniser (IKA Works, Wilmington, NC, USA). In the case of Na + ,K + -ATPase catalytic subunits (a1, a2 and a3 isoforms), crude homogenates were centrifuged for 3 min at 400 g to remove particulate matter. The supernatants were then centrifuged for 1 h at 100 000 g, and the pellets, containing membrane fraction, were resuspended in lysis buffer without Nonidet P-40. In the case of MBP, crude homogenates were used directly. The protein concentration of each sample was assayed relative to the bovine serum albumin standard according to the method of Bradford (33) . In the case of Na + ,K + -ATPase catalytic subunits, equal amounts of each sample were solubilised in 0.1% sodium decyl sulphate (SDS) sample buffer, left for 45 min at 37°C, resolved on a 8% SDS-polyacrylamide gel, and electroblotted overnight to a nitrocellulose membrane (Trans-blot; Bio-Rad, Milan, Italy). In the case of MBP, equal amounts of each sample were solubilised in 0.1% SDS sample buffer, left for 5 min at 100°C, resolved on a 20% SDS-polyacrylamide gel. The membrane was blocked at room temperature in PBS with added 0.1% Tween 20 and 5% nonfat dried milk. Successively, the filters were cut and the top was incubated overnight at 4°C with either mouse monoclonal antibody against a3 (ABR, Indianapolis, IN, USA), rabbit polyclonal against a2 (Upstate, Milan, Italy), rabbit antiserum against a1 (Upstate) or MBP (Millipore, Billerica, MA, USA). Primary antibodies were diluted 1 : 1000 in PBS buffer-0.1% Tween 20-3% nonfat dried milk. The filters were then washed for 30 min and incubated in secondary antiserum, horseradish peroxidase-conjugated goat antirabbit IgG for a2 and a1 or anti-mouse for a3 (Sigma-Aldrich) diluted 1 : 2000 or anti-rat horseradish peroxidase-conjugated secondary antibody (Millipore) diluted 1 : 10 000. In parallel, the bottom filters were incubated with a primary monoclonal anti-b-actin antibody (Sigma-Aldrich) diluted 1 : 10 000, as an internal control, then washed and incubated with an antimouse horseradish peroxidase-conjugated secondary antibody, diluted 1 : 10 000 (Amersham, Milan, Italy). After washing of filters, bound antibodies were detected with the ECL method (Amersham).
Blot data analysis
The protein expression for a1, a2, a3 isoforms, for MBP and for b-actin was calculated by measuring the peak densitometric area of the autoradiography acquired with a Kodak Snap Scanner (Kodak, Rochester, NY, USA) and analysed by IMAGEJ 1.33 (NIMH, Bethesda, MD, USA). To ensure that the autoradiographic bands were in the linear range of intensity, different exposure times were used. The mean control value within a single experiment was set to 100 and all the other values were expressed as a percentage. Values of controls from different experiments were all within 10%.
LC-MS ⁄ MS analysis
5-Pregnen-3b-ol-20-one (PREG), progesterone (PROG), 5a-pregnane-3, 20-dione (DHP), 5a-pregnan-3a-ol-20-one (THP), 5a-pregnan-3b-ol-20-one (isopregnanolone) were purchased from Sigma Aldrich. Positive atmospheric pressure chemical ionisation (APCI+) experiments were performed with a linear ion trap-mass spectrometer (LTQ; ThermoFisher Co., San Jose, CA, USA) using nitrogen as sheath, auxiliary and sweep gas. The instrument was equipped with a Surveyor liquid chromatography Pump Plus and a Surveyor Autosampler Plus (ThermoFisher Co.). The mass spectrometer was employed in MS ⁄ MS mode using helium as collision gas.
The LC mobile phases were: (A) H 2 O ⁄ 0.1% formic acid and (B) methanol (MeOH) ⁄ 0.1% formic acid. The gradient (flow rate 0.5 ml ⁄ min) was: T 0 70%A, T 1.5 70%A, T 2 55%A, T 3 55%A, T 35 36%A, T 40 25%A, T 41 1%A, T 45 1%A, T 45.2 70%A, T 55 70%A. The split valve was set at 0-6.99 min to waste, 6.99-43.93 min to source and 43.93-55 to waste. The Hypersil Gold column (100 · 3 mm, 3 lm; ThermoFisher Co.) was maintained at 40°C. The injection volume was 25 ll and the injector needle was washed with MeOH ⁄ -water 1 ⁄ 1 (v ⁄ v). Peaks of the LC-MS ⁄ MS were evaluated using a Dell workstation (Dell Corp., Round Rock, TX, USA) by means of the software Excalibur, release 2.0 SR2 (ThermoFisher Co.).
The spinal cords of rats (60-80 mg tissue) were extracted and purified according to Caruso et al. (34) for the quantitative evaluation of neuroactive steroids. Briefly, samples were added with internal standards, homogenised in 2 ml of MeOH ⁄ acetic acid (99 : 1 v ⁄ v) using a tissue lyser (Qiagen, Milan, Italy). After overnight extraction at 4°C, samples were centrifuged at 18 500 g for 5 min and the pellet was extracted twice with 1 ml of MeOH ⁄ acetic acid (99 : 1 v ⁄ v). The organic phases were combined and dried with a gentle stream of nitrogen in a 40°C water bath. The samples were passed through SPE cartridges, and the steroids were eluted in MeOH, concentrated and transferred in autosampler vials before LC-MS ⁄ MS analysis.
PROG levels in plasma of EAE animals treated with vehicle or with PROG were assessed as described previously (35) .
Quantitative analysis was performed on the basis of calibration curves prepared and analysed using deuterated internal standards. Calibration curves were extracted and analysed as described above for the samples. Limits of quantification, precision and accuracy have been reported previously (34, 36, 37) .
The linearity of the standard curve (r 2 ) was judged by GRAPHPAD4 PRISM, version 4 (GraphPad Software, La Jolla, CA, USA).
Statistical analysis
The quantitative data obtained by the experiments were analysed by inferential statistical analysis in accordance with the experimental protocols and the nature of the data (i.e. Student's t-test or ANOVA followed by Tukey's or Dunnett's post-hoc tests, as indicated). P < 0.05 was considered significant. All analyses were performed using GRAPHPAD PRISM, version 4.
Results
PROG treatment resulted in a significant increase in plasma PROG levels (0.40 AE 0.04 pg ⁄ ll versus 3.18 AE 1.06 pg ⁄ ll in vehicle-and PROG-injected animals, respectively; Student's t-test: P < 0.05).
The clinical score was used to detect the onset and course of EAE. As shown in Fig. 1(A) , clinical observations confirmed a peak of EAE onset in DA rats on days 12-14, as well as a protracted relapsing course of EAE characterised by at least one relapse in the follow-up period, with the earliest occurring on day 19 and the latest on day 43. PROG treatment did not alter EAE onset but, as shown in Fig. 1(B) , significantly reduced cumulative disease index (i.e. the mean sum of clinical scores over the entire observation period) (38, 39) .
Because inflammation comprises a hallmark of EAE related to the progression of the disease, we focused our attention on the ability of PROG to modulate the inflammatory response developed within the CNS at the relapse. Thus, we monitored the response developed within the CNS at 45 days and sustained by both local microglia and by peripheral infiltrating cells, such as lymphocytes and macrophages. As a marker for microglial reactivity, we measured MHC-II immunoreactive cells both in the white and grey matter of the spinal cord (Fig. 2) .
Qualitative inspection of the sections revealed marked differences in MHC-II immunoreactivity among the different experimental groups. Vehicle-treated EAE animals showed higher MHC-II immunoreactivity than control rats both in the white and grey matter ( Fig. 2A-D) , indicating a prolonged local inflammatory response. By contrast, MHC-II immunoreactivity was decreased in EAE animals injected with PROG compared to vehicle-injected EAE animals ( Fig. 2D-F) . The morphometric analysis of the number of MHC-II immunoreactive cells in the white matter region located between the dorsal horns confirmed the qualitative observations (Fig. 3) . The number of MHC-II immunoreactive cells was significantly increased in vehicle-treated EAE animals versus control rats. EAE animals treated with PROG showed a significant decrease in the number of MHC-II immunoreactive cells compared to vehicle-treated EAE animals.
Although microglia localisation observations suggested the persistence of an inflammatory response, immunohistological characterisation of the infiltrating cells in the spinal cord on day 45 for controls and EAE animals revealed very few CD3 + and ED1 + cells predominantly located in the perivascular space, and PROG treatment did not significantly modify this pattern (data not shown). The production and release of a plethora of mediators (among which are the pro-and anti-inflammatory cytokines) is a functional consequence of glial activation. To determine whether PROG decreased MHC-II expressing cells, resulting in a modulation of cytokine production within the CNS, gene expression of IL-1b, TNFa and TGF-b1 was measured in the spinal cord of control and EAE animals at day 45. Spinal cord specimens obtained from control rats express low levels of IL-1b mRNA (Fig. 4A) and TGF-b1 mRNA (Fig. 4B ), which were increased in EAE animals and significantly reduced by PROG treatment (Fig. 4) . The same trend (even if did not reach statistical significance) was observed for TNF-a gene expression [Control (n = 7): 2 )DDCT = 0.126; EAE + V (n = 6):
2 )DDCT = 1.000; EAE + PROG (n = 7): 2 )DDCT = 0.508]. Na + ,K + -ATPase plays a crucial role in controlling neuronal excitability by maintaining electrochemical gradients for Na + and K + across the plasma membranes (40, 41) . As shown in Fig. 5 , the enzymatic activity of Na + ,K + -ATPase pump was significantly decreased in the spinal cord of chronic EAE compared to that observed in control animals. PROG treatment was able to completely counteract this decrease. As shown in Fig. 6 , chronic EAE induced a slight decrease in the expression of Na + ,K + -ATPase catalytic subunits (a1, a2 and a3 isoforms); however, only in the case of a2 isoform did the decrease reach statistical significance. PROG treatment was unable to significantly change the expression levels of all the three isoforms in the spinal cord of chronic EAE. As shown in Fig. 7 , chronic EAE induced a significant decrease of MBP expression and PROG treatment was able to counteract this effect.
PROG is actively metabolised in the nervous system. Therefore, the levels of PROG and their metabolites (i.e. DHP, THP and isopregnanolone) were evaluated in the spinal cord of chronic EAE by LC-MS ⁄ MS. As shown in Fig. 8 , the levels of PROG in the spinal cord (Fig. 8A) were significantly decreased in chronic EAE. Treatment with PROG increased its low levels occurring in EAE (Fig. 8A) , even if not in a significant way and induced a significant increase of DHP (Fig. 8B) and isopregnanolone (Fig. 8D ) levels.
Discussion
The findings obtained in the present study indicate that chronic treatment with PROG, which results in high plasma levels of the steroid, ameliorates the clinical score together with biochemical parameters related to damage in chronic EAE. These results extend the previous reported findings in the acute phase of the disease (12) (13) (14) 17) to a condition that is more comparable to human MS. The protective action of PROG during the chronic phase of EAE strongly supports the potential therapeutic benefits of this steroid in MS.
Initiation of EAE involves the activation of myelin-specific Th1 or Th17 cells, which in turn trigger the expansion of resident microglia and the recruitment of blood-borne myelomonocitic cells (42, 43) . Conversely, the fundamental mechanisms leading to the distinct stages of relapsing and remitting disease remain unclear. Our findings indicate that later phases of EAE are associated predominantly with an increase in the number of MHC-II immunoreactive cells in the spinal cord.
MHC-II is expressed in professional antigen-presenting cells, such as macrophages and reactive microglia (29) . Our findings indicate that EAE is associated with an increase in the number of MHC-II immunoreactive cells in the spinal cord. PROG administration reduced the number of MHC-II cells in EAE animals. The changes in the number of MHC-II immunoreactive cells probably reflect differences in microglia activation because most MHC-II immunoreactive cells represent activated microglial cells (29) and only a few ED1+ cells were located in the perivascular space. Our findings suggest, therefore, that PROG is able to decrease the activation of microglia in EAE with a long-lasting effect.
MS is associated with a cytokine storm characterised by the parallel up-regulation of pro-inflammatory (i.e. IL-1b, TNF-a) and immune response-down-regulating (i.e. TGF-b1) cytokines, produced by microglia, astrocytes and infiltrating cells. Accordingly, microglial activation in later phases of EAE is associated with an increased expression of IL-1b, TNF-a and TGF-b1, and PROG treatment significantly counteracted such an increase. The observation that PROG decreases indistinctly the expression of both pro-and anti-inflammatory cytokines could be attributed to a general extinction of microglial response.
The extinction of microglia response by PROG in EAE could be also related to the recovery of Na + ,K + -ATPase activity. As previously reported for the acute phase of EAE (13), in the present study, we observed a defect in the activity of the Na + ,K + -ATPase pump and a recovery of its function in PROG-treated animals, which is independent from an altered expression of its subunits. Impaired activity of the Na + ,K + -ATPase is a primary mechanism of acute injury in the setting of conditions associated with failure of oxidative mitochondrial metabolism and ATP production. It has been recently reported that a mitochondrial respiratory chain complex IV defect occurs in demyelinated areas of MS patients (44) . Complexes I, II, III and IV are components of the mitochondrial respiratory chain related to the complex V, which is directly involved in ATP synthesis (45, 46) . Therefore, a defect of these complexes may reflect a general energy deficit, also affecting the activity of the Na + ,K + -ATPase pump.
Moreover, a significant inverse correlation between the density of microglia ⁄ macrophages and complex IV activity also occurred in demyelinated areas of MS patients (44) , possibly as a result of the evidence indicating that: (i) axonal injury correlates with inflammation; (ii) microglia ⁄ macrophages are a source of reactive oxygen species (ROS) in MS lesions; and (iii) complex IV is susceptible to ROS-mediated damage (47) . These findings might suggest that the protective effect of PROG observed on Na + ,K + -ATPase pump is mediated by the decrease of MHC-II immunoreactive cells and cytokine levels. Indeed, in many experimental models, PROG treatment has been demonstrated to directly influence microglial cells (48) (49) (50) (51) (52) . On the other hand, as previously demonstrated in other experimental models (53, 54) , an effect of PROG mediated by astroglial ⁄ oligodendroglia compartments on microglial cells could be also possible.
In the present study, we have demonstrated that PROG treatment was also able to counteract the decreased of MBP expression observed in the spinal cord during chronic phase of EAE. This find- mRNA levels in control (n = 7) and experimental autoimmune encephalomyelitis (EAE) animals injected with vehicle (V; n = 6) or with progesterone (PROG; n = 7). Gene expression was determined by real-time polymerase chain reaction in the spinal cord of control and EAE rats 45 days after the induction. Gene expression is given as the mean AE SEM. Data were analysed by ANOVA followed by Tukey's post-hoc test. ***P < 0.001 versus control animals, # P < 0.05, ## P < 0.01 and ### P < 0.001 versus EAE animals injected with vehicle.
ing extends previous observations showing an effect of PROG in acute phase of the disease (13, 55) and in other experimental models of neurodegeneration (56) (57) (58) (59) (60) and suggests another promyelinating effect of this neuroactive steroid. The protective effect of PROG could be exerted by the steroid itself and ⁄ or by conversion into its metabolites. Indeed, in the CNS, including macroglial and microglial compartments, PROG is converted into DHP, THP and isopregnanolone (26, 61) . These metabolic conversions have a deep impact in the mechanism of action of PROG. Indeed, although DHP, similar to its precursor PROG, is able to interact with PROG receptor, the further DHP metabolites, THP and isopregnanolone, exert their effects by the modulation of a nonclassical steroid receptor, such as GABA A receptor. In particular, THP is a well-known positive modulator of GABA A receptor (62, 63) . Although isopregnanolone does not bind directly to the GABA A receptor (64) , it antagonises the effect of THP on the GABAA receptor (65) (66) (67) .
Recent observations obtained in our laboratory have suggested that, in the spinal cord of DA EAE animals, the levels of neuroactive steroids are modified by the disease (35, 68) . However, EAE features may depend on several parameters, such as, for example, the method used for pathology induction. Accordingly, we have applied a different EAE model, inducing DA rats with syngenic whole spinal cord homogenate suspended in IFA.
Using LC-MS ⁄ MS analysis, we observed that the present experimental model not only showed similarities, but also several differences compared to that previously observed in DA rats where EAE was induced with guinea-pig whole spinal cord homogenate suspended in complete Freund's adjuvant (CFA) (35, 68) . In particular, at variance to DA-CFA EAE rats (35) , where PROG showed only a tendency to decrease during the chronic phase and DHP was significantly decreased in the spinal cord, in DA-IFA rats, PROG shows a significant decrease, whereas DHP levels were unaffected.
The functional significance of the changes in the levels of neuroactive steroids in the spinal cord during the different phases of EAE is unknown. Because PROG is an immunosuppressor, reduces reactive gliosis, increases the expression of MBP and promotes remyelination and oligodendrocyte differentiation (26, 59, (69) (70) (71) , its decreased levels in the spinal cord during the chronic phase of the disease may compromise the regeneration process. The data -ATPase pump, detected by western blotting, in the spinal cord of control (n = 6) and experimental autoimmune encephalomyelitis (EAE) animals injected with vehicle (V; n = 6) or with progesterone (PROG; n = 6). The columns represent the mean AE SEM after normalisation with b-actin. Data were analysed by ANOVA followed by Tukey's post-hoc test. **P < 0.01 versus control animals.
obtained after PROG treatment in EAE animals in the present study indicate an increase of the levels of both DHP and isopregnanolone. PROG and DHP may directly act on classical PROG receptors to decrease neural damage.
Microglial cells also express GABA A receptor (72) and, consequently, could be a possible target for the action of THP, which is known to be neuroprotective in different brain injury models (73) (74) (75) . Indeed, it has been recently reported that GABA suppresses the activation of microglia and associated neuroimmunological features (72) and, even if in a different model of EAE and with a different time course, THP appears to exert a beneficial effect (76) . However, under our experimental conditions, we observed that PROG treatment was unable to modify the levels of THP but significantly increased those of the isopregnanolone that (as mentioned above) antagonises the effect of THP on the GABA A receptor. These findings appear to exclude a role of THP and GABA A receptor in mediating the protective effects of PROG observed in the present study. Therefore, our findings suggest that the neuroprotective actions of PROG in our experimental model may be mediated by DHP acting on PROG receptors.
In conclusion, the results obtained in the present study indicate that PROG therapy is effective in reducing the spinal cord damage caused by chronic EAE. This finding gives support to the potential use of PROG as a therapeutic tool for the treatment of MS. 
